← Back to news
NewsFDAFriday, June 20, 2025 · June 20, 2025

Elevidys Gene Therapy Receives Full FDA Approval for Duchenne MD

WHY IT MATTERS

First gene therapy for Duchenne with full approval. Sets precedent for rare neuromuscular diseases.

Sarepta Therapeutics received full FDA approval for Elevidys for ambulatory Duchenne muscular dystrophy patients aged 4-5.

Read the original at FDA
FDA ApprovalGene Therapy

Related conditions

Duchenne muscular dystrophy